Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine

Vaccine

Volumn 17, Issue 15-16, 1999, Pages 2073-2080

  Johansson, Bert E ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Influenza; Neuraminidase; Vaccines

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; SIALIDASE;

ANIMAL EXPERIMENT; ARTICLE; BACULOVIRUS; FEMALE; IMMUNE RESPONSE; INFECTION PREVENTION; INFLUENZA VIRUS A; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, VIRAL; BACULOVIRIDAE; BINDING, COMPETITIVE; CELL LINE; DOGS; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS; INFLUENZA VACCINES; LUNG; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; PLAQUE ASSAY; VACCINES, SYNTHETIC; VIRAL LOAD; VIRUS REPLICATION;

EID: 0033538014     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00413-7     Document Type: Article

References (31)

1. Davenport F. Control of influenza. Med. J. Aust. 1(Suppl.):1973;33.
2. Barker W., Mullooly J. Pneumonia and influenza deaths during epidemics: implications for prevention. Arch. Intern. Med. 142:1982;85.
3. Gross P., Quinnan G., Rodstem M.et al. Association of influenza immunization with reduction in mortality in an elderly population: a prospective study. Arch. Intern. Med. 148:1988;562.
4. Kilbourne E. Influenza: viral determinants of the pathogenicity and epidemicity of an invariant disease of variable occurrence. Philos. Trans. R. Soc. L. [Biol.]. 288:1980;291.
5. Johansson B., Bucher D., Kilbourne E. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J. Virol. 63:1989;1239.
6. Hocart M., Grajower B., Donabedian A., Pokorny B., Whitaker C., Kilbourne E. Preparation and characterization of a purified influenza virus neuraminidase vaccine. Vaccine. 13:1995;1793.
7. Hobson D., Curry A., Beare A., Ward-Gardner A. Hemagglutination inhibition antibody titers as a measure of protection against influenza in man. Dev. Biol. Stand. 20:1973;164.
8. Powers D., Kilbourne E., Johansson B. Neuraminidase-specific antibody responses to inactivated influenza vaccine in young and elderly adults. Clin. Diag. Lab. Immunol. 3:1996;511.
9. Gross P., Ennis F., Gaerlan L., Denson L., Denning C., Schiffinan D.A. Controlled double-blind comparison of the reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. J. Inf. Dis. 136:1977;623.
10. Kendal A., Noble G., Dowdle W. Neuraminidase content of influenza vaccines and neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. J. Inf. Dis. 136:1977;S145.
11. Kendal A., Bozeman F., Ennis F. Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. Infect. Immun. 29:1980;966.
12. Johansson B., Kilbourne E. Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition. Proc. Natl. Acad. Sci. USA. 91:1994;2358.
13. Johansson B., Moran T., Bona C., Popple S., Kilbourne E. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience. J. Immunol. 139:1987;2010.
14. Johansson B., Moran T., Bona C., Kilbourne E. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. III. Reduced generation of neuraminidase-specific helper T cells in hemagglutinin-primed mice. J. Immunol. 139:1987;2015.
15. Johansson B.E., Matthews L.T., Kilbourne E.D. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine. 16(9):1998;1009-1015.
16. Johansson B., Kilbourne E. Immunization with dissociated neuraminidase, matrix and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition. Virology. 225:1996;136.
17. Archetti J., Horsfall F. Persistent antigenic variation of influenza A virus after incomplete neutralization in ovo with heterologous immune serum. J. Exp. Med. 92:1950;1521.
18. Johansson B., Kilbourne E. Comparative long term effects in a mouse model system of influenza whole virus vaccine and purified neuraminidase vaccine followed by sequential infections. J. Inf. Dis. 162:1991;800.
19. Kilbourne E., Grajower B., Johansson B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase. Proc. Natl. Acad. Sci. USA. 87:1990;786.
20. Johansson B., Price P., Kilbourne E. Immunogenicity of influenza A virus N2 neuraminidase produced in insect larvae by baculovirus recombinants. Vaccine. 9:1995;841.
21. Price P., Reichelderfer C., Johansson B., Kilbourne E., Acs G. Complementation of recombinant baculovirus by coinfection with wild-type virus facilitates production in insect larvae of antigenic proteins of hepatitis B virus and influenza virus. Proc. Natl. Acad. Sci. USA. 86:1989;1453.
22. Lowry O.H., Rosebrough N.J., Farr A.C., Radall R.I. Protein measurement with the folin-phenol reagent. J. Biol. Chem. 193:1951;265.
23. Sever J. Application of a microtechnique to viral serological investigations. J. Immunol. 88:1962;320.
24. Jahiel R., Kilbourne E. Reduction in plaque number as differing indices of influenza virus-antibody reactions. J. Bacteriol. 92:1966;1521.
25. Johansson B., Moran T., Kilbourne E. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc. Natl. Acad. Sci. USA. 84:1987;6869.
26. Johansson B., Kilbourne E. Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J. Virol. 67:1993;5721.
27. Kilbourne E. Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in the induction of anti-neuraminidase antibody in man. J. Inf. Dis. 134:1976;384.
28. Beutner K., Chow T., Rubi E., Strussenberg J., Clement J., Ogra P. Evaluation of a neuraminidase-specific influenza vaccine in children: antibody responses and effects of the successive outbreak of natural infection. J. Virol. 140:1979;844.
29. Couch R., Kasel J., Gerin J., Schulman J., Kilbourne E. Induction of partial immunity to influenza by a neuraminidase-specific influenza A virus vaccine in humans. J. Inf. Dis. 129:1974;411.
30. Kilbourne E., Couch R., Kasel J., Keitel J., Cate T., Quarles J., Grajower B., Pokorny B., Johansson B. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and nontoxic in humans. Vaccine. 13:1995;1799.
31. Powers D.C., Smith G.E., Anderson E.L.et al. Influenza A vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults. J. Inf. Dis. 171:1995;1595-1599.